• In April 2026, Arteris, Inc. announced an expanded collaboration with MIPS, a GlobalFoundries company, which will integrate Arteris’ FlexGen smart NoC IP and Magillem SoC integration automation software into MIPS’ RISC-V–based platforms for physical AI applications across automotive MCUs, ADAS, robotics, and embedded computing.
• This deeper integration into the MIPS ecosystem suggests Arteris’ system IP could become an important building block in future AI-enabled SoC designs, broadening its reach across multiple end markets.
• We’ll now examine how embedding Arteris FlexGen NoC IP into MIPS’ RISC-V physical AI platforms could influence the company’s investment narrative.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

Arteris Investment Narrative Recap

To own Arteris, I think you need to believe its system IP becomes a core ingredient in increasingly complex AI and automotive chips, while the company manages persistent losses and heavy investment. The expanded MIPS collaboration reinforces the near term catalyst of deeper RISC V and physical AI adoption, but it does not remove the biggest risk, which is that high operating costs and customer concentration could still strain margins if design activity slows or large deals do not repeat.

Among recent announcements, the expanded collaboration with NXP in February 2026 looks especially relevant, since it also embeds Arteris IP more deeply into AI enabled automotive and edge platforms. Taken together with the new MIPS deal, it reinforces the idea that FlexGen, FlexNoC and Magillem are becoming part of critical design flows across several major ecosystems, which could support the current revenue growth trajectory but also amplifies the stakes if any of these large partners change course.

Yet beneath these promising design wins, a key issue investors should be aware of is the ongoing losses and the question of how long Arteris can...

Arteris' narrative projects $130.9 million revenue and $15.0 million earnings by 2029.

Uncover how Arteris' forecasts yield a $20.50 fair value, a 29% downside to its current price.

Exploring Other Perspectives

Some of the highest analysts were already assuming around 24.5% annual revenue growth to about US$136.2 million by 2029, which is far more optimistic than consensus. In light of the new MIPS deal and the concern that open source and vertically integrated NoC alternatives could limit Arteris’s addressable market, you should recognize how widely opinions differ and consider how both narratives might evolve from here.

Explore 4 other fair value estimates on Arteris - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arteris research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Arteris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arteris' overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.